The primary obstacle to leveraging AI in bioprocessing isn't developing advanced models, but solving the pre-existing, complex challenge of data readiness. Companies are still struggling to unify disparate data from different tools, sites, and GMP vs. development environments, turning intended "data lakes" into inaccessible "data swamps."

Executive enthusiasm for AI often overlooks a critical dependency: the availability of underlying organizational data. Projects initiated top-down, based on impressive LLM demos, frequently fail because the company lacks the necessary data infrastructure to support the proposed workflow.

The conventional wisdom that enterprises are blocked by a lack of clean, accessible data is wrong. The true bottleneck is people and change management. Scrappy teams can derive significant value from existing, imperfect internal and public data; the real challenge is organizational inertia and process redesign.

The bottleneck for AI in drug discovery is not the algorithm but the lack of high-quality, large-scale biological data. New platforms are needed to generate this necessary "substrate" for AI models to learn from, challenging the narrative that better models alone are the solution.

The primary bottleneck for creating powerful foundation models in biology is the lack of clean, large-scale experimental data—orders of magnitude less than what's available for LLMs. This creates a major opportunity for "data foundries" that use robotic labs to generate high-quality biological data at scale.

The primary barrier to implementing AI for antibody developability isn't the tech, which has been available for over a decade. MIT's Bernhard Trout states the real failure point is a lack of sustained corporate commitment, as key personnel are frequently reassigned to other projects, causing initiatives to stall.

For industries like healthcare and finance, the primary obstacle to deploying AI isn't the technology's capability but the state of their own data. Many organizations lack the proper data formatting and security infrastructure, making it impossible to "unleash" AI on their most valuable information.

The primary barrier to successful AI implementation in pharma isn't technical; it's cultural. Scientists' inherent skepticism and resistance to new workflows lead to brilliant AI tools going unused. Overcoming this requires building 'informed trust' and effective change management.

The biggest obstacle to AI adoption is not the technology, but the state of a company's internal data. As Informatica's CMO says, "Everybody's ready for AI except for your data." The true value comes from AI sitting on top of a clean, governed, proprietary data foundation.